ARTL ARTELO BIOSCIENCES, INC.

Nasdaq artelobio.com


$ 4.07 $ 0.01 (0.24 %)    

Tuesday, 14-Oct-2025 15:59:50 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 4.14
$ 4.10
$ 4.05 x 1
$ 5.00 x 2
$ 4.05 - $ 4.22
$ 4.00 - $ 28.60
112,669
na
5.47M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-25-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 01-12-2022 11-30-2021 10-Q
16 11-29-2021 08-31-2021 10-K
17 07-12-2021 05-31-2021 10-Q
18 04-13-2021 02-28-2021 10-Q
19 01-14-2021 11-30-2020 10-Q
20 11-04-2020 08-31-2020 10-K
21 07-13-2020 05-31-2020 10-Q
22 04-13-2020 02-29-2020 10-Q
23 01-14-2020 11-30-2019 10-Q
24 11-25-2019 08-31-2019 10-K
25 07-15-2019 05-31-2019 10-Q
26 04-15-2019 02-28-2019 10-Q
27 01-14-2019 11-30-2018 10-Q
28 11-29-2018 08-31-2018 10-K
29 07-13-2018 05-31-2018 10-Q
30 04-16-2018 02-28-2018 10-Q
31 01-16-2018 11-30-2017 10-Q
32 11-29-2017 08-31-2017 10-K
33 07-21-2017 05-31-2017 10-Q
34 04-14-2017 02-28-2017 10-Q
35 01-10-2017 11-30-2016 10-Q
36 11-29-2016 08-31-2016 10-K
37 07-05-2016 05-31-2016 10-Q
38 04-01-2016 02-29-2016 10-Q
39 01-14-2016 11-30-2015 10-Q
40 12-11-2015 08-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 artelo-biosciences-prices-20m-public-offering

SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutic...

 artelo-biosciences-announces-publication-of-new-preclinical-data-on-art1211-proprietary-cannabidioltetramethylpyrazine-cocrystal

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...

 d-boral-capital-downgrades-artelo-biosciences-to-hold

D. Boral Capital analyst Jason Kolbert downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.

 artelo-biosciences-drug-helps-cancer-patients-regain-weight-eyes-licensing-deal

Artelo Biosciences reported encouraging Phase 2 trial results for ART27.13 in cancer anorexia-cachexia syndrome, citing strong ...

 artelo-biosciences-announces-interim-results-from-phase-2-cares-trial-with-art2713-peripherally-acting-cannabinoid-receptor-agonist-for-treatment-of-cacs

Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACSConsistent Im...

 d-boral-capital-maintains-buy-on-artelo-biosciences-maintains-18-price-target

D. Boral Capital analyst Jason Kolbert maintains Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $18 price target.

 artelo-biosciences-announced-results-from-its-preliminary-food-effect-evaluation-with-art2612-as-a-part-of-the-single-ascending-dose-phase-1-trial-for-persistent-pain

Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted ConditionsCompletion of Positive Single Ascending D...

 on-aug-19-artelo-biosciences-terminates-securities-purchase-agreement

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION